Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model

Human Gene Therapy

Volumn 26, Issue 2, 2015, Pages 82-93

  Huang, Tiffany T ^a   Parab, Shraddha ^a   Burnett, Ryan ^a   Diago, Oscar ^a   Ostertag, Derek ^a   Hofman, Florence M ^b   Espinoza, Fernando Lopez ^a   Martin, Bryan ^a   Ibañez, Carlos E ^a   Kasahara, Noriyuki ^c   Gruber, Harry E ^a   Pertschuk, Daniel ^a   Jolly, Douglas J ^a   Robbins, Joan M ^a  

^a Tocagen   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCYTOSINE; GREEN FLUORESCENT PROTEIN; VIRUS DNA; VOCIMAGENE AMIRETROREPVEC; ANTIMETABOLITE; CYTOSINE DEAMINASE; FUNGAL PROTEIN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CANCER SURVIVAL; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG UPTAKE; FEMALE; GLIOMA; IMMUNE RESPONSE; IMMUNOCOMPETENCE; INTRACRANIAL DRUG ADMINISTRATION; LONG TERM SURVIVAL; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; RETROVIRUS; TISSUE LEVEL; VIRUS REPLICATION; ADMINISTRATION AND DOSAGE; ANIMAL; BRAIN NEOPLASMS; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE MODEL; GENE EXPRESSION; GENE THERAPY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MORTALITY; NUDE MOUSE; PATHOLOGY; PHARMACOKINETICS; PRECLINICAL STUDY; PROCEDURES; REPORTER GENE; RETROVIRIDAE; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION;

ANIMALIA; MUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIMETABOLITES; BRAIN NEOPLASMS; CLINICAL TRIALS AS TOPIC; CYTOSINE DEAMINASE; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; FLUCYTOSINE; FUNGAL PROTEINS; GENE EXPRESSION; GENES, REPORTER; GENETIC THERAPY; GENETIC VECTORS; GLIOMA; GREEN FLUORESCENT PROTEINS; HUMANS; INJECTIONS, INTRAVENOUS; MICE; MICE, NUDE; RECOMBINANT PROTEINS; RETROVIRIDAE; SURVIVAL ANALYSIS; TISSUE DISTRIBUTION;

EID: 84923211486     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2014.100     Document Type: Article

References (38)

1. Ostertag D, Amundson KK, Lopez Espinoza F, et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. Neurooncology 2012; 14:145-159.
2. Perez OD, Logg CR, Hiraoka K, et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. Mol Ther 2012;20:1689-1698.
3. Tai CK, Wang WJ, Chen TC, et al. Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma. Mol Ther 2005;12:842-851.
4. Lin AH, Burrascano C, Pettersson PL, et al. Blockade of type I IFN production by retroviral replicating vectors and reduced tumor cell responses to IFN likely contribute to tumor selectivity. J Virol 2014;88:10066-10077.
5. Wang WJ, Tai CK, Kasahara N, et al. Highly efficient and tumor-restricted gene transfer to malignant gliomas by replication-competent retroviral vectors. Hum Gene Ther 2003;14:117-127.
6. Inada T, Ichikawa A, Kubota T, et al. 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Anticancer Res 1997;17:1965-1971.
7. Pritchard DM, Watson AJ, Potten CS, et al. Inhibition by uridine but not thymidine of p53-dependent intestinal apoptosis initiated by 5-fluorouracil: evidence for the involvement of RNA perturbation. Proc Natl Acad Sci U S A 1997;94:1795-1799.
8. Backus HH, Wouters D, Ferreira CG, et al. Thymidylate synthase inhibition triggers apoptosis via caspases-8 and -9 in both wild-type and mutant p53 colon cancer cell lines. Eur J Cancer 2003;39:1310-1317.
9. Matuo R, Sousa FG, Escargueil AE, et al. 5-Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell line. J Appl Toxicol 2009;29:308-316.
10. Silverstein RA, Gonzalez de Valdivia E, and Visa N. The incorporation of 5-fluorouracil into RNA affects the ribonucleolytic activity of the exosome subunit Rrp6. Mol. Cancer Res 2011;9:332-340.
11. Barresi V, Belluardo N, Sipione S, et al. Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. Cancer Gene Ther 2003;10:396-402.
12. Chen JK, Hu LJ, Wang D, et al. Cytosine deaminase/ 5-fluorocytosine exposure induces bystander and radiosensitization effects in hypoxic glioblastoma cells in vitro. Int J Radiat Oncol Biol Phys 2007;67:1538-1547.
13. Chang DY, Yoo SW, Hong Y, et al. The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. Int J Cancer 2010;127:1975-1983.
14. Hlavaty J, Jandl G, Liszt M, et al. Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma. J Neurooncol 2011;102:59-69.
15. Pohl U, Wick W, Weissenberger J, et al. Characterization of Tu-2449, a glioma cell line derived from a spontaneous tumor in GFAP-v-src-transgenic mice: comparison with established murine glioma cell lines. Int J Oncol 1999;15: 829-834.
16. Wesseling P, Ruiter DJ, and Burger PC. Angiogenesis in brain tumors; Pathobiological and clinical aspects. J Neurooncol 1997;32:253-265.
17. Linkous AG, and Yazlovitskaya EM. Angiogenesis in glioblastoma multiforme: navigating the maze. Anticancer Agents Med Chem 2011;11:712-718.
18. Bloch O, Crane CA, Kaur R, et al. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res 2013;19: 3165-3175.
19. DePolo NJ, Harkleroad CE, Bodner M, et al. The resistance of retroviral vectors produced from human cells to serum inactivation in vivo and in vitro is primate species dependent. J Virol 1999;73:6708-6714.
20. Shashkova EV, Doronin K, Senac JS, et al. Macrophage depletion combined with anticoagulant therapy increases therapeutic window of systemic treatment with oncolytic adenovirus. Cancer Res 2008;68:5896-5904.
21. Smith JS, Xu Z, Tian J, et al. Interaction of systemically delivered adenovirus vectors with Kupffer cells in mouse liver. Hum. Gene Ther 2008;19:547-554.
22. Fan H. Leukemogenesis by Moloney murine leukemia virus: a multistep process. Trends Microbiol 1997;5:74-82.
23. Dawson PJ, and Fieldsteel AH. The influence of age on chronic remittent Friend disease. Cancer Res 1971;31:974-980.
24. Yamada Y, Matsushiro H, Ogawa MS, et al. Genetic predisposition to pre-B lymphomas in SL/Kh strain mice. Cancer Res 1994;54:403-407.
25. Tang JC, Ho FC, Chan AC, et al. Clonality of lymphomas at multiple sites in SJL mice. Lab Invest 1998;78:205-212.
26. Bonzon C, and Fan H. Moloney murine leukemia virusinduced preleukemic thymic atrophy and enhanced thymocyte apoptosis correlate with disease pathogenicity. J Virol 1999;73:2434-2441.
27. Zhang L, Thrasher AJ, and Gaspar HB. Current progress on gene therapy for primary immunodeficiencies. Gene Ther 2013;20:963-969.
28. Powell JS, Ragni MV, White II, GC, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. Blood 2003;102:2038-2045.
29. Cornetta K, Moen RC, Culver K, et al. Amphotropic murine leukemia retrovirus is not an acute pathogen for primates. Hum Gene Ther 1990;1:15-30.
30. Roehl HH, Leibbrandt ME, Greengard JS, et al. Analysis of testes and semen from rabbits treated by intravenous injection with a retroviral vector encoding the human factor VIII gene: no evidence of germ line transduction. Hum Gene Ther 2000;11:2529-2540.
31. McCormack JE, Edwards W, Sensintaffer J, et al. Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. Mol Ther 2001;3:516-525.
32. Xu L, Haskins ME, Melniczek JR, et al. Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus based retroviral vector results in long-term expression of b-glucuronidase in mucopolysaccharidosis VII dogs. Mol Ther 2002;5:141-153.
33. Huhtala T, Kaikkonen MU, Lesch HP, et al. Biodistribution and antitumor effect of Cetuximab-targeted lentivirus. Nucl Med Biol 2014;41:77-83.
34. Tao N, Gao GP, Parr M, et al. Sequestration of adenoviral vector by Kupffer cells leads to a nonlinear dose response of transduction in liver. Mol Ther 2001;3:28-35.
35. High KA. The gene therapy journey for hemophilia: are we there yet? Blood 2012;120:4482-4487.
36. Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006;13:221-228.
37. Geletneky K, Huesing J, Rommelaere J, et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer 2012;12:99.
38. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. Gene Ther 2001;8:746-759.